Cilostazol in patients with heart failure and preserved ejection fraction—The CLIP‐HFpEF trial
• Cilostazol is an oral PDE‐3 inhibitor that may have advantageous effects in heart failure with preserved ejection fraction (HFpEF). • Cilostazol significantly improved short‐term heart failure‐related health status scores (KCCQ‐12) and NT‐proBNP levels when compared to placebo.
Norman Aiad+9 more
wiley +1 more source
Pro-C-Type Natriuretic Peptide in Women With Angina Pectoris and No Obstructive Coronary Artery Disease. [PDF]
Mark PD+5 more
europepmc +1 more source
Atrial Natriuretic Peptide Infusion in Chronic Heart Failure in the Rat
Masahiro Kohzuki+4 more
openalex +1 more source
The Rab3 GTPase cycle modulates cardiomyocyte exocytosis and atrial natriuretic peptide release. [PDF]
Essandoh K+3 more
europepmc +1 more source
Atrial natriuretic peptide concentrations in pre-eclampsia:: Authors' reply [PDF]
J. K. Thomsen+4 more
openalex +1 more source
The effect of different water temperatures on the release of the atrial natriuretic factor (ANF) during "head out water immersion (HOI)" [PDF]
Arendt, Rainer M.+5 more
core +1 more source
Heart Failure With Preserved Ejection Fraction and Low B-type Natriuretic Peptide: A Diagnostic Dilemma. [PDF]
Paul T+4 more
europepmc +1 more source
Cis-Active Determinants of Cardiac-Specific Expression in the Human Atrial Natriuretic Peptide Gene [PDF]
Jiangping Wu+4 more
openalex +1 more source
The advanced lung cancer inflammation index (ALI) is an integrated marker of inflammation and nutritional status, calculated by body mass index × serum albumin / neutrophil‐to‐lymphocyte ratio. Low ALI levels were significantly associated with poor prognosis in elderly multimorbid HFpEF patients.
Daisuke Sakamoto+19 more
wiley +1 more source